Lamda Variants, the new coronavirus mutation that is thought to have increased resistance to vaccines, has appeared in the United States. The variant is also known as C.37. This variant was first discovered in peru.
Peru has been one of the countries hit hardest by the pandemic, with 595 COVID-19 deaths per 100,000 people, the highest in the world. Peru has relied heavily on the Chinese vaccine known as Sinopharm, which is 79% effective at preventing hospitalizations. The Pfizer and Moderna vaccines are 94% effective against hospitalization.
According to global science initiative GISAID, the Lamda Variants has spread to eight countries in South America and 41 countries around the world. A spokesman of the Centers for disease controland prevention said that there are currently more than 1,300 cases of C.37 sequences in the U.S. as of August 4, 2021, and the Lamda Variants has been identified in 44 states. The variant was detected in a woman in her 30s at Haneda Airport who arrived from Peru on July 20. She tested positive for the coronavirus in a quarantine check at the airport, with no symptoms. The virus was confirmed to be of the Lamda Variants in an analysis by the National Institute of Infectious Diseases.
Compared with the conventional strain, the variant may be more infectious and have stronger resistance to vaccines, but its details are not known, the institute said. Meanwhile, the Delta variant is challenging the part of the world that’s been most successful in blunting the economic impact of COVID-19, with Asian countries that snuffed it out locking down again as the virus returns.